91![Microsoft Word - osteoporosis-int.doc Microsoft Word - osteoporosis-int.doc](https://www.pdfsearch.io/img/730f4b5eccf4a952d93fa16ce9a2fffc.jpg) | Add to Reading ListSource URL: www.hivclinic.caLanguage: English - Date: 2013-11-04 13:43:31
|
---|
92![NOVA SCOTIA PROVINCIAL PHARMACARE PROGRAMS Request for Coverage of Osteoporosis Therapy PATIENT INFORMATION PATIENT SURNAME PATIENT GIVEN NAME NOVA SCOTIA PROVINCIAL PHARMACARE PROGRAMS Request for Coverage of Osteoporosis Therapy PATIENT INFORMATION PATIENT SURNAME PATIENT GIVEN NAME](https://www.pdfsearch.io/img/09d4c06891db04d77ea24667d0b64c61.jpg) | Add to Reading ListSource URL: novascotia.caLanguage: English - Date: 2014-01-06 14:13:30
|
---|
93![Division: Pharmacy Services Subject: Prior Authorization Criteria Original Development Date: Original Effective Date: Division: Pharmacy Services Subject: Prior Authorization Criteria Original Development Date: Original Effective Date:](https://www.pdfsearch.io/img/4b0e050af637fdafcf2321d118a808f6.jpg) | Add to Reading ListSource URL: www.ahca.myflorida.comLanguage: English - Date: 2012-06-25 14:43:19
|
---|
94![962 Zoledronic Acid Delays the Onset of Skeletal-Related Events and Progression of Skeletal Disease in Patients with Advanced Renal Cell Carcinoma Allan Lipton, M.D.1 962 Zoledronic Acid Delays the Onset of Skeletal-Related Events and Progression of Skeletal Disease in Patients with Advanced Renal Cell Carcinoma Allan Lipton, M.D.1](https://www.pdfsearch.io/img/8850420830e6c5405f3f8103c90235dc.jpg) | Add to Reading ListSource URL: www.kidneycancercanada.caLanguage: English - Date: 2012-11-27 15:44:00
|
---|
95![PRODUCT MONOGRAPH XGEVA Pr PRODUCT MONOGRAPH XGEVA Pr](https://www.pdfsearch.io/img/54d2358f71e79be5942bc30738b23eb0.jpg) | Add to Reading ListSource URL: www.amgen.caLanguage: English - Date: 2014-10-10 12:55:23
|
---|
96![Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tu Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tu](https://www.pdfsearch.io/img/ee74c36279dab738f3dcd95ef0ce2fca.jpg) | Add to Reading ListSource URL: www.kidneycancercanada.caLanguage: English - Date: 2012-11-27 15:44:03
|
---|
97![Division: Pharmacy Services Subject: Prior Authorization Criteria Original Development Date: Original Effective Date: Division: Pharmacy Services Subject: Prior Authorization Criteria Original Development Date: Original Effective Date:](https://www.pdfsearch.io/img/0f99c535d236901ffbc9f64bdf2f9f83.jpg) | Add to Reading ListSource URL: www.fdhc.state.fl.usLanguage: English - Date: 2012-06-25 14:31:43
|
---|
98![Program # Abstract Title 2011 SABCS Disclosure Report F. Name M. Name L. Name Program # Abstract Title 2011 SABCS Disclosure Report F. Name M. Name L. Name](https://www.pdfsearch.io/img/798a1a8efa4ded12f84d2a7d1f039ef2.jpg) | Add to Reading ListSource URL: www.sabcs.orgLanguage: English - Date: 2012-02-27 11:38:46
|
---|
99![Skeletal system / Bisphosphonates / Osteopathies / Chemical pathology / Alendronic acid / Merck / Bisphosphonate / Osteoporosis / Denosumab / Medicine / Biology / Health Skeletal system / Bisphosphonates / Osteopathies / Chemical pathology / Alendronic acid / Merck / Bisphosphonate / Osteoporosis / Denosumab / Medicine / Biology / Health](/pdf-icon.png) | Add to Reading ListSource URL: courses.washington.eduLanguage: English - Date: 2012-03-23 17:01:02
|
---|
100![Division: Pharmacy Services Subject: Prior Authorization Criteria Original Development Date: Original Effective Date: Division: Pharmacy Services Subject: Prior Authorization Criteria Original Development Date: Original Effective Date:](https://www.pdfsearch.io/img/7f9115bc80c01fdad028dd20d2c22e51.jpg) | Add to Reading ListSource URL: www.ahca.myflorida.comLanguage: English - Date: 2012-06-25 14:31:43
|
---|